Cancer vaccines have undergone a renaissance because of recent clinical trials showing promising immunologic data and some clinical benefit to patients. Current trials exploiting dendritic cells (DCs) as vaccines have shown durable tumor regressions in a fraction of patients. Clinical efficacy of current vaccines is hampered by myeloid-derived suppressor cells, inflammatory type 2 T cells, and regulatory T cells, all of which prevent the generation of effector cells. To improve the clinical efficacy of DC vaccines, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome regulatory T cells and allow the breakdown of the immunosuppressive tumor microenvironment. This can be achieved by exploiting the fast increasing knowledge about the DC system, including the existence of distinct DC subsets. Critical to the design of better vaccines is the concept of distinct DC subsets and distinct DC activation pathways, all contributing to the generation of unique adaptive immune responses. Such novel DC vaccines will be used as monotherapy in patients with resected disease and in combination with antibodies and/or drugs targeting suppressor pathways and modulation of the tumor environment in patients with metastatic disease.
M olecular identification of human cancer antigens has ushered in a new era of antigen-specific cancer immunotherapy specifically targeting these antigens. One strategy is the transfusion of T cells, also called adoptive T-cell therapy (reviewed in Ref. 1) . In this case, antigen-specific T cells are expanded ex vivo and transfused to patients. Adoptive T-cell therapy has been shown to be an effective treatment for viral infections 2 and has induced regression of cancer in early-stage clinical trials. 3, 4 Another strategy is to expand T cells in vivo by means of vaccination. Initial attempts at vaccination (eg, peptides, DNA vaccines, viral vectors, and first generation dendritic cell [DC]-based vaccines) have thus far met with a limited success in the clinic. However, cancer vaccines are undergoing a renaissance because of increased knowledge on the regulation of immune responses and recent clinical trials showing promising immunologic data and some clinical benefit to the patients. For example, an active immunotherapy product, Sipuleucel-T (APC8015) based on antigen-loaded and granulocyte-macrophage colony-stimulating factor (GM-CSF) activated peripheral blood mononuclear cells, seems to contribute to prolonged median survival in phase III trials in patients with prostate cancer. 5 Sipuleucel-T has been recently approved by the Food and Drug Administration for treatment of metastatic prostate cancer thereby paving the regulatory path for the next generation of active immunotherapy products. A randomized phase II trial of a poxviral-based vaccine targeting prostate-specific antigen (PROSTVAC) in men with metastatic castration-resistant prostate cancer showed improved overall survival in patients who received PROSTVAC compared with patients receiving control vectors. 6 Although these first-generation, positive, randomized phase II/III clinical trials need further analysis and mechanistic studies, they underline the therapeutic potential of the immune system that can be tapped in. Vaccines act through DCs that induce, regulate, and maintain T-cell immunity. Herein, we summarize our recent studies that aimed at a better understanding of the DC system to unravel the pathophysiology of cancer and to design novel DC-based cancer vaccines with enhanced clinical relevance.
DENDRITIC CELLS
T-cell priming is under the control of DCs. In the steady state, nonactivated (immature) DCs present self-antigens to T cells, which leads to tolerance. 7, 8 DCs induce immune tolerance in a number of ways including (i) T-cell deletion, 9 -11 (ii) induction of T-cell unresponsiveness, 12 and (iii) activation of regulatory T cells (Tregs). [13] [14] [15] [16] Once activated (mature), antigen-loaded DCs are geared toward the launching of antigen-specific immunity, 17, 18 leading to the T-cell proliferation and differentiation into helper and effector cells ( Fig.  1 ). DCs are also important in launching humoral immunity partly because of their capacity to directly interact with B cells 19, 20 and to present unprocessed antigens. [21] [22] [23] [24] To allow resistance to infection and tolerance to self, DCs are endowed with 2 critical features: subsets and functional plasticity. 25 The 2 major subsets are the myeloid DCs (mDCs) and the plasmacytoid DCs (pDCs). The best studied human mDC subsets are those from skin, where 3 subsets can be identified. The epidermis hosts only Langerhans cells (LCs), whereas the dermis displays 2 mDC subsets, CD1a ϩ DCs and CD14 ϩ DCs, and macrophages. 26 -29 pDCs are considered as the front line in antiviral immunity due to their capacity to rapidly produce high amounts of type I interferon (IFN). 30, 31 Similar to mDCs (as discussed in detail below), pDCs display a remarkable functional plasticity. Thus, pDCs exposed to viruses, such as live influenza virus, are able to launch memory responses by inducing the expansion and differentiation of antigenspecific memory B and T lymphocytes into plasma cells, 32 and cytotoxic T lymphocyte (CTLs), 33, 34 respectively. On the contrary, pDCs activated with CpG or interleukin (IL)-3/CD40L induce in vitro IL-10-secreting regulatory CD4 ϩ T cells 35 and suppressor CD8 ϩ T cells through the expression of inducible T-cell COstimulator ligand. 36 Their role in active immunotherapy of cancer is largely undefined. Below, we will discuss in a greater detail the recent advances in our understanding of the biology of mDCs because it applies to vaccination.
Dermal DCs, Antibody Responses, and IL-12
In the mid 1990s, we observed that CD14 ϩ DCs derived from CD34 ϩ hematopoietic progenitor cells induce CD40-activated naïve B cells to differentiate into IgM-producing plasma cells through the secretion of IL-6 and IL-12. 37 A decade later, we found that CD14 ϩ DCs, but not LCs, induce naive CD4 ϩ T cells to differentiate into cells with properties of T follicular helper cells (Tfh), 27 a CD4 ϩ T cell subset specialized in B cell help. 38, 39 In this case, CD4 ϩ T cells primed by CD14 ϩ DCs help naive B cells to produce large amounts of IgM and switch isotypes toward IgG and IgA. Our recent studies in human indicate that acquisition of Tfh phenotype and function depends on IL-12p70. 40 Thus, IL-12 seems to contribute to humoral immunity in humans through a direct path in DC-B interaction, and an indirect path in DC-T cell interaction and induction of Tfh cells. These findings might explain the modest clinical efficacy of systemic IL-12 administration in cancer patients. 41, 42 Furthermore, the injection of IL-12 into tumor sites of head and neck cancer patients resulted in the activation of B cells in the draining lymph nodes, which was associated with their infiltration into tumor sites and tumor regression. 43
LCs and CD8 ؉ T-Cell Responses
LCs induce a robust proliferation of naive allogeneic CD8 ϩ T cells when compared with CD14 ϩ DCs. 27 Furthermore, when pulsed with major histocompatibility complex (MHC) class I peptides derived from tumor or viral antigens, LCs are far more efficient than CD14 ϩ DCs in the priming of antigen-specific CD8 ϩ T cells. LCs are also efficient in cross-presenting peptides from protein antigens to CD8 ϩ T cells. CD8 ϩ T cells primed by LCs show high avidity in tetramer binding assays and express higher levels of cytotoxic molecules, such as granzymes and perforin. Accordingly, they are remarkably more efficient in killing target cells, in particular tumor cells that express low level of peptide/human leukocyte antigen (HLA) complexes. 27 IL-15 might explain the remarkable effects of LCs on the development of CTL responses. 44 -46 Thus, the 2 different arms of adaptive immunity, ie, humoral and cellular arms, might be differentially regulated by the 2 skin mDC subsets ( Fig. 1 ). Such framework might be of capital importance for the understanding of the immune alteration in malignancy and for development of novel FIGURE 1. Dendritic cells. Dendritic cells (DCs) reside in the tissue in which they are poised to capture antigens. 109 During inflammation, circulating precursor DC enter tissues as immature DC. 109 DCs can encounter pathogens (eg, viruses) directly, which induce secretion of cytokines (eg, interferon [IFN]-␣) or indirectly through the pathogen effect on stromal cells. Cytokines secreted by DCs in turn activate effector cells of innate immunity such as eosinophils, macrophages, and natural killer (NK) cells. Microbe activation triggers DCs migration toward secondary lymphoid organs and simultaneous activation (maturation). These activated migratory DCs that enter lymphoid organs display antigens in the context of classic major histocompatibility complex (MHC) class I and class II or nonclassic CD1 molecules, which allow selection of rare circulating antigenspecific T lymphocytes. Activated T cells help drive DCs toward their terminal maturation, which allows lymphocyte expansion and differentiation. Activated T lymphocytes traverse inflamed epithelia and reach the injured tissue, where they eliminate microbes and microbe-infected cells. B cells, activated by DCs and T cells, migrate into various areas at which they mature into plasma cells that produce antibodies that neutralize the initial pathogen. Antigen can also reach draining lymph nodes without involvement of peripheral tissue DCs and be captured and presented by lymph node resident DCs. 110 The quality of antibody responses is determined by intDCs, whereas the quality of CTL responses is dictated by LCs. and improved vaccination strategies against cancer and chronic infections.
DENDRITIC CELLS IN VACCINATION AGAINST CANCER

Outcomes of Current DC Vaccination Trials
Ex vivo-generated DCs have been used as therapeutic vaccines in patients with metastatic cancer for more than a decade and early studies have been discussed in detail elsewhere. 47 Although a fraction of patients can experience durable tumor regressions, 48 the most common outcome of the current DC vaccination protocols is a demonstration of expanded antigen-specific immunity, most often using IFN-␥ ELISPOT, but no durable objective tumor regression.
Altogether, the following 3 outcomes emerge from our studies:
1. No immune response. Patients of this group usually progress quickly. These patients mount immune responses to control antigens such as KLH or viral peptides (Flu-M1 or CMV). In vitro experiments indicated that T cells of several patients can be primed to differentiate into CTLs with specificity for multiple melanoma antigens. 49 Thus, tumor antigen-specific CD8 ϩ T cells are kept anergic rather than deleted. This inability to mount immune responses to tumor antigens in vivo might be at least partly related to the presence of tumor antigen-specific Tregs. 50, 51 Tregs limit the onset of protective immunity through several mechanisms, for example by eliminating DCs in lymph nodes. 52 As discussed later, the control of Tregs becomes a key target to address for the future vaccination trials. 2. Immune response without clinical response. The most common outcome of current DC vaccination protocols is the induction of immune responses in the absence of clinical responses. This might in part be explained by the quality of the elicited T cells including their capacity to migrate into tumors and penetrate tumor stroma. 53 Improved immunomonitoring is expected to provide insights into the mechanisms of immune efficacy as discussed below. 54,55 3. Immune response and clinical response. Vaccination with DCs can elicit therapeutic immunity. These patients represent a formidable opportunity for the development of cancer immunotherapy. The challenge is 2-fold. First, to establish the immunologic mechanism that allowed tumor eradication. Second, we need to find ways to increase the fraction of patients experiencing durable tumor regression or prolonged survival.
The Quality of Elicited Antigen-Specific Immune Responses
Establishing causative links in clinical studies is a difficult task, which often requires large patient cohorts. The current data suggest an association between the tumor-specific CD8 ϩ T-cell responses and clinical outcomes. In our view, 4 critical components will determine whether the induced immune response will be therapeutic: (1) the quality of elicited CTLs, (2) the quality of induced CD4 ϩ helper T cells, (3) the elimination and/or nonactivation of Tregs, and (4) the breakdown of immunosuppressive tumor microenvironment.
Indeed, the immune responses elicited by the first generation DC vaccines might not be of the quality required to allow the rejection of bulky tumors. For example, the induced T cells might not migrate into the tumor lesions. 56, 57 Furthermore, low-avidity T cells might be unable to recognize peptide-MHC class I complexes on tumor cells and to kill them. 56 Finally, the tumor microenvironment might inhibit effector T-cell functions, for example, by action of myeloid-derived suppressor cells and Tregs as summarized in recent reviews. 58, 59 The recent progresses in immunomonitoring of specific immune responses in the blood and at the tumor site should help us address these questions. 48, 50, 54, 55, 60 Modern approaches including polychromatic flow cytometry rather than the analysis of a single cytokine (eg, IFN-␥ ELISPOT) and frequency of tetramer positive cells will contribute to a better assessment of the quality of the immune responses elicited in the patients. 61, 62 Indeed, several studies, mostly performed in the context of HIV vaccines, have led to the conclusion that a mere measurement of the frequency of IFN-␥ secreting CD8 ϩ T cells is insufficient to evaluate the quality of vaccine-elicited immunity. 56, 63, 64 
BUILDING ON DENDRITIC CELL SUBSETS TO IMPROVE CANCER VACCINES
Optimal DCs
The results summarized above prompted us to hypothesize that DCs with the properties of LCs might prove to be the best ones for the generation of strong cellular immunity (Fig. 1 ). In line with this, the combination of cytokines used to differentiate monocytes into DCs play a critical role in determining the quality of the elicited T-cell responses. For example, DCs generated with GM-CSF and IL-15 display the phenotype and characteristics of LCs. In particular, they are more efficient in priming melanoma antigen-specific CD8 ϩ T cells in vitro than DCs derived with GM-CSF and IL-4. 44, 45 Thus, vaccination with IL15-DCs might elicit stronger CD8 ϩ T-cell responses that might lead to improved clinical responses. We are currently initiating such a clinical trial in patients with malignant melanoma. The selection of methods for activating DCs also represents a critical parameter in the design of DC vaccines. First, immature (nonactivated) DCs induce antigen-specific IL-10-producing T cells. 65, 66 Second, IL-4 DCs activated with a cocktail of IFN-␣, polyI:C, IL-1␤, TNF, and IFN-␥ induce up to 40 times more melanoma-specific CTLs in vitro than DCs matured with the "standard" cocktail of IL-1␤/TNF/IL-6/prostaglandin E 2 . [67] [68] [69] Additional studies will be necessary to establish the therapeutic value of the newer generation DC vaccines in patients. Besides the quality of CD8 ϩ T cells, the quality of CD4 ϩ T cells will become one of the key parameters of immune efficacy. These studies are critical to the understanding of the human immune system because they permit us to assess in vivo the type of immune responses elicited by human DCs generated in different cytokine environments.
This in turn is essential for building a novel approach to vaccination that is based on the delivery of antigens directly to DCs in vivo using chimeric proteins that are made of an anti-DC receptor antibody molecularly fused to a selected antigen (DC targeting). Studies in mice demonstrate that the specific targeting of antigen to DCs in vivo results in considerable potentiation of antigen-specific CD4 ϩ and CD8 ϩ T-cell immunity. The induction of immunity is observed only when the DC maturation signal is provided 7, 70, 71 and, otherwise, tolerance ensues. 7 Thus, selection of appropriate adjuvant is also a critical parameter for the induction of the immunity of the desired type. Although toll-like receptor ligands are widely considered to promote protective immunity against infectious agents, selecting the appropriate ligand will be critical. For instance, tolllike receptor-2 ligation, which promotes the induction of Tregs rather than T H 1 or Th17 cells, 72 does not seem to be a preferred option for cancer vaccines.
These pioneering studies have been already extended to demonstrate the targeting of tumor antigens to DCs 73 and LCs in animal models 74, 75 and the generation of antitumor immunity. 76 The therapeu-
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Optimal Antigen Loading
Although much attention has been paid to CD8 ϩ T cells, CD4 ϩ T cells have long been known to be involved in antitumor immunity. 77 A number of recent studies in murine models of cancer suggests the role of tumor antigen-specific CD4 ϩ T cells in antitumor immunity, which seem to act through different mechanisms including (i) help in the expansion of tumor antigen-specific CTLs, 78 (ii) activation of macrophages at tumor sites, 79, 80 and (iii) active killing of tumor cells. 81, 82 Furthermore, it is now well established that antigen-specific CD4 ϩ T cells are fundamental for the induction of long-term memory CD8 ϩ T cells. 83 Aiming at the induction of tumor antigen-specific CD4 ϩ T-cell responses, DC vaccines loaded with tumor antigen-derived HLA class II peptides 84 or transduced with a vector encoding a defined tumor antigen 85 have been tested in metastatic melanoma and shown to induce tumor antigen-specific CD4 ϩ T-cell responses. Whether vaccination results in the development of durable memory CD4 ϩ T cell, response remains to be established.
Intimately linked to the quality of CD4 ϩ T-cells, responses is the nature of the antigen and the way to load tumor antigen on DC vaccines. As illustrated in Figure 2 , in our own studies, we have started loading DC vaccines with short tumor antigen-derived peptides that can be presented by MHC class I. These were combined with KLH as a foreign helper antigen with the idea to provide CD4 ϩ T cell help via generation of new CD4 ϩ T-cell responses. Both antigens elicited immune responses, and we found long-lived melanoma-specific CD8 ϩ T cells in some patients. 86 -88 Loading DCs with exogenous peptides that bind MHC class I molecules can generate a limited set of high-quality antigen-specific CD8 ϩ T cells. However, peptides are limited to certain HLA types and to known tumor antigens. Furthermore, there is no evidence that the currently used melanoma-derived tumor antigens might be the best targets for vaccination. Foreign helper antigens (such as KLH) can be used to prime helper T cells and potentially avoid reactivation of tumor antigen-specific Tregs. However, human tumor antigen-specific CD4 ϩ T cells might prove to be more efficient in their helper function for tumor antigen-specific CD8 ϩ T cells. An alternative strategy to generate broad immune responses is to load DCs with complex antigen preparations such as tumor-derived RNA 89 or killed tumor cells. 90 Loading DCs with killed tumor cells builds on the unique capacity of DCs to present internalized antigens via MHC class I leading to cross-priming of naive CD8 ϩ T cells. A major advantage is that it is not limited to a selected haplotype such as HLA-A*0201. We have shown that DCs loaded with killed allogeneic tumor cells FIGURE 2. Loading antigen on ex vivo dendritic cells (DC) vaccines. A number of ways by which the antigen can be delivered to DCs have been identified. The advantages and disadvantages are discussed. Currently, we are developing the strategy to load DCs with long peptides representing defined tumor antigens and providing both CD8 ϩ and CD4 ϩ T-cell epitopes.
FIGURE 3. Dendritic cells (DC) vaccines in combination
therapies. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current approaches is limited, possibly because tumors invade the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells. To improve the clinical efficacy of immunotherapies, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs, and allow the breakdown of an immunosuppressive tumor microenvironment. This can be achieved by developing combination therapies targeting these 3 major components.
The Cancer Journal • Volume 16, Number 4, July/August 2010 Dendritic Cells and Cancer from melanoma, 49, 91 prostate cancer, 92 and breast cancer 93, 94 can cross-prime naive HLA-A*0201 ϩ CD8 ϩ T cells to differentiate into CTLs specific for defined tumor antigens. It also has the potential to allow presentation of tumor antigens on MHC class II molecules for tumor-specific help. Type 1 CD8 ϩ T-cell immunity to MART-1 was found in 3 of 13 patients with metastatic melanoma who received 8 DC vaccines loaded with killed allogeneic melanoma cells. 48 Two of these patients showed improved immunity in response to vaccination with DCs. Indeed, increased frequency of the specific CD8 ϩ T cells and/or their proliferation in response to MART-1-derived peptides indicated in vivo cross-presentation of melanoma antigens by DC vaccine. In 1 patient, vaccination led to elicitation of IFN-␥ producing CD8 ϩ T cells specific to a MART-1 peptide to which no response could be detected at the onset. This suggests that in vivo DC vaccines loaded with killed allogeneic melanoma cells are capable of cross-priming. However, a potential limitation of such strategy is the expansion of tumor antigen-specific regulatory/suppressor cells. Furthermore, the assessment of immune responses in such trials represents a challenge because both antigens and their T-cell epitopes and HLA restriction elements are largely unknown. Recently, we begun to assess the immune and clinical efficacy of DC vaccines loaded with long peptides derived from selected tumor antigens so as to allow the presentation of epitopes for both CD8 ϩ and CD4 ϩ T cells (Fig. 2 ).
Combining DC Vaccines With Other Therapies
In view of the remarkable diversity of regulatory/suppressive pathways present in patients with metastatic cancer, any durable clinical response elicited by vaccination with DCs is already a remarkable achievement. However, to improve the outcomes in metastatic disease, DC vaccines need to be combined with other therapies that offset the suppressive environment created by tumors. 95 Such combination regimens will involve several drugs that target different pathways (Fig. 3) .
In particular, blocking antibodies or soluble receptors can be exploited for the blockade of suppressive cytokines in the tumor microenvironment such as IL-10, 96 IL-13, 97 transforming growth factor beta, 98, 99 and vascular endothelial growth factor. 100, 101 Such strategies can be used to block immune-inhibitory signals in lymphocytes as illustrated by anti-CTLA-4 102,103 and anti-PD1, 104 -106 or to block their ligands expressed on tumors or DCs (for example anti-PD-L1). In contrast, agonistic antibodies 100,101 might further promote costimulation of effector T cells as for example with anti-CD137, 107 a ligand for 4 -1BB. 108 Because different tumors are treated with different combinations of cytostatic drugs and targeted therapies, we foresee development of clinical protocols combining DC vaccines with individualized adjunct therapies.
CONCLUDING REMARKS
The considerable progress made in the knowledge of DC biology and effector/Treg biology has clearly opened avenues for development of vastly improved clinical protocols. These optimized DC vaccines eliciting strong and long-lived antigen-specific CD8 ϩ and CD4 ϩ T-cell immunity will be offered to patients with earlystage disease. For patients with late-stage disease, strategies that combine novel highly immunogenic DC-based vaccines and immunomodulatory antibodies will have high effect on enhancing therapeutic immunity in cancer by simultaneously enhancing the potency of beneficial immune arms and offsetting immunoregulatory pathways ( Fig. 3) . These optimized therapeutic strategies will be tailored to a single patient level, including strategies to break suppressive pathways ( Fig. 4) .
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